Kyowa Kirin Co., Ltd. (4151.T) JPX

2,315.00

-55(-2.32%)

Updated at June 03 11:30AM

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Abdul Hafeez Mullick	President, Chief Executive Officer & Representative Director	157M	1967
Masashi Miyamoto	Chairman & Chief Executive Officer	157M	1959
Nilay Gami	Head of Global Pharmacovigilance	0	N/A
Nathan Hawes	Global Operational & Digital Transformation Head	0	N/A
Hiroshi Sonekawa	Managing Executive Officer, Vice President and Head of Sales & Marketing Division	0	N/A
Naohiko Kubo	Global Finance Head & Accounting Manager	0	N/A
Motohiko Kawaguchi	Chief Financial Officer & Managing Executive Officer	0	N/A
Takaaki Uochi	Head of Global Compliance & Risk Management	0	N/A
Hiroki Nakamura	Global Corporate Communications Head	0	N/A
Koichi Nagano	Executive Officer and Head of Tokyo Branch - Sales & Marketing Division	0	N/A
Koji Igarashi	Chief Financial Officer	0	N/A
Masahiro Hara	Global Procurement Head	0	N/A
Katsuyoshi Tsukii	Executive Officer, VP & Head of Development Division	0	N/A
Takeyoshi Yamashita	Executive VP, Chief Scientific Officer & Director	0	1961
Eslie Dennis	Global Medical Affairs Head	0	N/A
Kazuki Nemoto	Head of Global Legal	0	N/A
Shoko Itagaki	Managing Executive Officer, Chief People Officer & Global Human Resources Head	0	N/A
Yasuo Fujii	Chief Business Officer, VP, Managing Executive Officer & Global Business Development Head	0	1964
Yoshifumi Torii	Executive Officer, Chief Medical Officer & Global Development Head	0	N/A
Stacey Minton	Global Corporate Communications Head	0	N/A

Name

Title

Pay

Year Born

Abdul Hafeez Mullick

President, Chief Executive Officer & Representative Director

157M

1967

Masashi Miyamoto

Chairman & Chief Executive Officer

157M

1959

Nilay Gami

Head of Global Pharmacovigilance

N/A

Nathan Hawes

Global Operational & Digital Transformation Head

N/A

Hiroshi Sonekawa

Managing Executive Officer, Vice President and Head of Sales & Marketing Division

N/A

Naohiko Kubo

Global Finance Head & Accounting Manager

N/A

Motohiko Kawaguchi

Chief Financial Officer & Managing Executive Officer

N/A

Takaaki Uochi

Head of Global Compliance & Risk Management

N/A

Hiroki Nakamura

Global Corporate Communications Head

N/A

Koichi Nagano

Executive Officer and Head of Tokyo Branch - Sales & Marketing Division

N/A

Koji Igarashi

Chief Financial Officer

N/A

Masahiro Hara

Global Procurement Head

N/A

Katsuyoshi Tsukii

Executive Officer, VP & Head of Development Division

N/A

Takeyoshi Yamashita

Executive VP, Chief Scientific Officer & Director

1961

Eslie Dennis

Global Medical Affairs Head

N/A

Kazuki Nemoto

Head of Global Legal

N/A

Shoko Itagaki

Managing Executive Officer, Chief People Officer & Global Human Resources Head

N/A

Yasuo Fujii

Chief Business Officer, VP, Managing Executive Officer & Global Business Development Head

1964

Yoshifumi Torii

Executive Officer, Chief Medical Officer & Global Development Head

N/A

Stacey Minton

Global Corporate Communications Head

N/A

Description

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.